Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

PI3K and cancer: lessons, challenges and opportunities

PI3K and cancer: lessons, challenges and opportunities Key PointsMutations that activate the phosphoinositide 3-kinase (PI3K) signalling network are nearly ubiquitous in human cancer.PI3K activation has central physiological roles in many normal cells and tissues, including those of the immune system.Small molecules have been generated that selectively inhibit PI3K, AKT or mammalian target of rapamycin (mTOR) with good pharmacological properties.As single agents, most PI3K–AKT–mTOR inhibitors are cytostatic rather than cytotoxic to cancer cells.Early results from clinical trials show limited activity of these agents as monotherapies, but a striking exception is GS-1101, which is a selective inhibitor of p110δ.Now is the time to re-evaluate strategies to develop and apply PI3K pathway inhibitors for treating cancer.This Review proposes four priorities to guide future efforts in translational and clinical research.The first is biomarker identification, which involves using next-generation sequencing to identify genetic correlates for rare responders.The second is haematological malignancies; following on the success of GS-1101, clinical trials of leukaemia and lymphoma provide advantages for pharmacodynamic monitoring and for harnessing the effects of pathway inhibitors on the tumour microenvironment.The third is immune effects, which involves taking advantage of the cell-extrinsic effects of PI3K–mTOR inhibitors that can enhance antitumour immunity under certain conditions.The last is combination trials; it is likely that PI3K pathway inhibitors will be most effective when applied in combination with other targeted inhibitors. Many such combinations are discussed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Reviews Drug Discovery Springer Journals

PI3K and cancer: lessons, challenges and opportunities

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/pi3k-and-cancer-lessons-challenges-and-opportunities-c0l33Gejf1

References (257)

Publisher
Springer Journals
Copyright
Copyright © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2014
Subject
Biomedicine; Biomedicine, general; Pharmacology/Toxicology; Biotechnology; Medicinal Chemistry; Molecular Medicine; Cancer Research
ISSN
1474-1776
eISSN
1474-1784
DOI
10.1038/nrd4204
Publisher site
See Article on Publisher Site

Abstract

Key PointsMutations that activate the phosphoinositide 3-kinase (PI3K) signalling network are nearly ubiquitous in human cancer.PI3K activation has central physiological roles in many normal cells and tissues, including those of the immune system.Small molecules have been generated that selectively inhibit PI3K, AKT or mammalian target of rapamycin (mTOR) with good pharmacological properties.As single agents, most PI3K–AKT–mTOR inhibitors are cytostatic rather than cytotoxic to cancer cells.Early results from clinical trials show limited activity of these agents as monotherapies, but a striking exception is GS-1101, which is a selective inhibitor of p110δ.Now is the time to re-evaluate strategies to develop and apply PI3K pathway inhibitors for treating cancer.This Review proposes four priorities to guide future efforts in translational and clinical research.The first is biomarker identification, which involves using next-generation sequencing to identify genetic correlates for rare responders.The second is haematological malignancies; following on the success of GS-1101, clinical trials of leukaemia and lymphoma provide advantages for pharmacodynamic monitoring and for harnessing the effects of pathway inhibitors on the tumour microenvironment.The third is immune effects, which involves taking advantage of the cell-extrinsic effects of PI3K–mTOR inhibitors that can enhance antitumour immunity under certain conditions.The last is combination trials; it is likely that PI3K pathway inhibitors will be most effective when applied in combination with other targeted inhibitors. Many such combinations are discussed.

Journal

Nature Reviews Drug Discovery – Springer Journals

Published: Feb 1, 2014

There are no references for this article.